Predicting response to infliximab and interferon-α in Behçet’s syndrome: An exploratory analysis from the BIO-BEHÇET’S randomized controlled trial
Authors:
Open Access
- 1 June 2025
- journal article
- research article
- Published by Walter de Gruyter GmbH in Rheumatology and Immunology Research
- Vol. 6 (2) , 70-79
Abstract
Background and Objectives: Biologic therapy has been used for Behçet’s Syndrome after first-line immunomodulation, but in the absence of high-quality evidence or predictive biomarkers. BIO-BEHÇET’S was a randomized controlled clinical trial to compare the two most widely used biologics for Behçet’s Syndrome at that time, infliximab versus interferon-α2a, and identify potential biomarkers for response. Methods: A total of 79 patients with active Behçet’s Syndrome were randomized to either infliximab (REMICADE) or interferon-α2a (ROFERON) according to the UK national treatment pathway, and follow-up with symptom-directed examination undertaken at Weeks 12 and 24. The head-to-head trial included an exploratory analysis on the potential role of single nucleotide polymorphisms (SNPs) and urinary metabolomic to act as biomarkers for drug response. Genotypic analysis was performed to determine whether four SNPs in IFNL3 and IFNL4 – selected based on known effects – impacted primary and secondary outcomes. For metabolomic analyses, urine samples were analyzed by nuclear magnetic resonance spectroscopy and principal component analysis. Results: Genetic data suggested potential association between outcomes and carriage of rs4803221 or rs7248668 variants in the IFNL3 (IL-28B) gene locus for interferon-α2a patients; however, with the relatively small sample, statistical significance was lost when corrected for multiple testing. Metabolomic analysis identified potential markers of metabolic response to infliximab. Conclusion: BIO-BEHÇET’S suggests there is potential for a novel metabolomic biomarker that can identify response to infliximab in patients with Behçet’s Syndrome. Further work will characterize the appropriate metabolite (s) from existing samples to inform future prospective trials to study this in more detail clinically.Keywords
This publication has 27 references indexed in Scilit:
- Potential metabolomic biomarkers for reliable diagnosis of Behcet's disease using gas chromatography/ time-of-flight-mass spectrometryJoint Bone Spine, 2018
- The immunogenetics of Behçet's disease: A comprehensive reviewJournal of Autoimmunity, 2015
- Metabolic Profiling Predicts Response to Anti–Tumor Necrosis Factor α Therapy in Patients With Rheumatoid ArthritisArthritis & Rheumatism, 2013
- A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virusNature Genetics, 2013
- Clinical utility of interleukin-28B testing in patients with genotype 1Hepatology, 2012
- Multicenter Study of Infliximab for Refractory Uveoretinitis in Behçet DiseaseArchives of Ophthalmology (1950), 2012
- Hepatitis C pharmacogenetics: State of the art in 2010Hepatology, 2010
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature, 2009
- The use of interferon α in behçet disease: review of the literatureSeminars in Arthritis and Rheumatism, 2004
- Treatment of Adamantiades-Behçet Disease With Systemic Interferon AlfaArchives of Dermatology, 1998